NEWS
As MC Sciences we have completed the year 2023 with achieving our science and drug development targets, successfully exceeded the original targets of our seed investment with rigid focus on value and execution.
We have started now the new year 2024 with high confidence and speed to progress our lead program over the next 9 months to best potential candidates as strong foundation for an attractive Series A. In early April, we will announce our official Series A timeline with data presentation events with locations and virtual sessions. Meet us also at the BioEquity in San Sebastian and the BIO2024 in San Diego.
MC Sciences is Finalist at the Start-Up Stadium at the BIO International in Boston. The presentation by Wolfgang Taumann, CEO of MC Sciences, will have the headline: “Sometimes the best drugs – are the most simple drugs”. The MC Sciences drug development is very unique and straightforward, enabled by the discovery of novel fascinating biology of the immune system. This is an exciting opportunity to present MC Sciences to a highly qualified audience at the BIO International in Boston.
MC Sciences is excited to formally announce its collaboration with ROC Venture Group, the lead investor of our seed investment upon completion of a thorough science due diligence. The seed investment enables MC Sciences to advance the pre-clinical drug development to a clear path to development candidates. Ryan Stephens and Aaron Stafford, both managing partners at ROC Venture Group, are members of the MC Sciences board.
Aaron Stafford, managing partner of ROC Venture Group, points out: “We are strongly convinced that the novel discovered therapeutic approach of MC Sciences will succeed to treat several diseases with high medical need. We are excited to be part of the MC Sciences journey to bring these highly needed novel therapeutics to patients, improve their lives and make an impact. We have seen Wolfgang build MC Sciences with incredible passion, combining outstanding leadership, science and execution skills together with a world-class team and top tier drug development partners.”
MC Sciences has achieved a significant breakthrough in the discovery of a novel receptor that controls and regulates the entire mast cell activity and targeted small molecules that selectively inhibit only the activated mast cells as foundation to develop the next generation mast cell therapeutics.
MC Sciences is a pre-clinical company developing the next generation therapeutics targeting mast cells. Chronically activated mast cells are key drivers in several diseases affecting large patient populations and the selective and complete inhibition of activated mast cells remains a high need. The primary focus is on selected diseases with high unmet need in the therapeutic areas of immunology, inflammation, dermatology, respiratory and gastroenterology.
Key asset of MC Sciences is the discovery of a novel receptor that controls and regulates the entire mast cell activity and corresponding small molecules that selectively inhibit only the activated mast cells (avoiding immune-suppressive side effects). The key objective of MC Science is the fundamental scientific investigation of the this novel discovered mast cell biology and to convert this discovery into a new therapeutic approach and a potential superior drug development.